Clinical management of portopulmonary hypertension

Hepatobiliary and Pancreatic Diseases International

Volumn 6, Issue 5, 2007, Pages 464-469

  Tam, Nga Lei ^a   He, Xiao Shun ^a  

^a SUN YAT SEN UNIVERSITY   (China)

Author keywords

Current development; Diagnosis; Pathogenesis; Portopulmonary hypertension; Therapy

Indexed keywords

BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; COUMARIN; GLYCERYL TRINITRATE; ILOPROST; NITRIC OXIDE; OXYGEN; PROSTACYCLIN; PROSTANOID; SHORT ACTING DRUG; SILDENAFIL; VASODILATOR AGENT;

CONSENSUS; DIAGNOSTIC ACCURACY; ECHOCARDIOGRAPHY; HEART CATHETERIZATION; LIVER DISEASE; LIVER TRANSPLANTATION; LUNG ARTERY PRESSURE; MEDLINE; MORBIDITY; MORTALITY; PATHOGENESIS; PERIOPERATIVE PERIOD; PORTAL HYPERTENSION; PORTOPULMONARY HYPERTENSION; PREVALENCE; PROGNOSIS; PULMONARY HYPERTENSION; REOPERATION; REVIEW; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE AGGREGATION INHIBITION; VASCULAR RESISTANCE;

ECHOCARDIOGRAPHY; HEART CATHETERIZATION; HUMANS; HYPERTENSION, PORTAL; HYPERTENSION, PULMONARY; LIVER TRANSPLANTATION; PLATELET AGGREGATION INHIBITORS; VASODILATOR AGENTS;

EID: 34948890580     PISSN: 14993872     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (34)

1. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996;17:17-33.
2. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology and clinical, laboratory and hemodynamic manifestations. J Am Coll Cardiol 1991;17: 492-498.
3. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet 1998;352:719-725.
4. Channick RN, Sitbon O, Barst RJ, Manes A, Rubin LJ. Endothelin receptor antagonists in pulmonary arterial hypertension. J Am Coll Cardiol 2004;43:62S-67S.
5. Sharma S, Kashour T, Philipp R. Secondary pulmonary arterial hypertension: treated with endothelin receptor blockade. Tex Heart Inst J 2005;32:405-410.
6. Pellicelli AM. Cytokines in portopulmonary hypertension. Gut 2004;53:1721.
7. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykoski RK, Edwards JE. Coexistent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987;10:1233-1238.
8. Jamison BM, Michel RP. Different distribution of plexiform lesions in primary and secondary pulmonary hypertension. Hum Pathol 1995;26:987-993.
9. Kim WR, Krowka MJ, Plevak DJ, Lee J, Rettke SR, Frantz RP, et al. Accuracy of Doppler echocardiography in the assessment of pulmonary hypertension in liver transplant candidates. Liver Transpl 2000;6:453-458.
10. Cotton CL, Gandhi S, Vaitkus PT, Massad MG, Benedetti E, Mrtek RG, et al. Role of echocardiography in detecting portopulmonary hypertension in liver transplant candidates. Liver Transpl 2002;8:1051-1054.
11. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
12. McLaughlin VV, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with longterm epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:273-277.
13. Krowka MJ, Frantz RP, McGoon MD, Severson C, Plevak DJ, Wiesner RH. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Hepatology 1999;30: 641-648.
14. Kato H, Katori T, Nakamura Y, Kawarasaki H. Moderate-term effect of epoprostenol on severe portopulmonary hypertension. Pediatr Cardiol 2003;24:50-53.
15. Kett DH, Acosta RC, Campos MA, Rodriguez MJ, Quartin AA, Schein RM. Recurrent portopulmonary hypertension after liver transplantation: management with epoprostenol and resolution after retransplantation. Liver Transpl 2001; 7:645-648.
16. Minder S, Fischler M, Muellhaupt B, Zalunardo MP, Jenni R, Clavien PA, et al. Intravenous iloprost bridging to orthotopic liver transplantation in portopulmonary hypertension. Eur Respir J 2004;24:703-707.
17. Halank M, Kolditz M, Miehlke S, Schiemanck S, Schmeisser A, Hoeffken G. Combination therapy for portopulmonary hypertension with intravenous iloprost and oral bosentan. Wien Med Wochenschr 2005;155: 376-380.
18. Kuntzen C, Gülberg V, Gerbes AL. Use of a mixed endothelin receptor antagonist in portopulmonary hypertension: a safe and effective therapy? Gastroenterology 2005;128:164-168.
19. Chua R, Keogh A, Miyashita M. Novel use of sildenafil in the treatment of portopulmonary hypertension. J Heart Lung Transplant 2005;24:498-500.
20. Makisalo H, Koivusalo A, Vakkuri A, Hockerstedt K. Sildenafil for portopulmonary hypertension in a patient undergoing liver transplantation. Liver Transpl 2004;10: 945-950.
21. Lepore JJ, Maroo A, Pereira NL, Ginns LC, Dec GW, Zapol WM, et al. Effect of sildenafil on the acute pulmonary vasodilator response to inhaled nitric oxide in adults with primary pulmonary hypertension. Am J Cardiol 2002; 90:677-680.
22. Michelakis E, Tymchak W, Lien D, Webster L, Hashimoto K, Archer S. Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation 2002;105:2398-2403.
23. Pirenne J, Verleden G, Nevens F, Delcroix M, Van Raemdonck D, Meyns B, et al. Combined liver and (heart-) lung transplantation in liver transplant candidates with refractory portopulmonary hypertension. Transplantation 2002;73:140-142.
24. Krowka MJ, Plevak DJ, Findlay JY, Rosen CB, Wiesner RH, Krom RA. Pulmonary hemodynamics and perioperative cardiopulmonary-related mortality in patients with portopulmonary hypertension undergoing liver transplantation. Liver Transpl 2000;6:443-450.
25. Mair P, Kaehler CH, Pomaroli A, Schwarz B, Vogel W, Margreiter R. Orthotopic liver transplantation in a patient with severe portopulmonary hypertension. Acta Anaesthesiol Scand 2001;45:513-518.
26. Robalino BD, Moodie DS. Primary pulmonary hypertension, then and now: 28 years of experience. Cleve Clin J Med 1992;59:411-417.
27. Hervé P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, et al. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-1166.
28. Swanson KL, Wiesner RH, Krowka MJ. Natural history of hepatopulmonary syndrome: Impact of liver transplantation. Hepatology 2005;41:1122-1129.
29. Kawut SM, Taichman DB, Ahya VN, Kaplan S, Archer-Chicko CL, Kimmel SE, et al. Hemodynamics and survival of patients with portopulmonary hypertension. Liver Transpl 2005;11:1107-1111.
30. Ramsay MA, Simpson BR, Nguyen AT, Ramsay KJ, East C, Klintmalm GB. Severe pulmonary hypertension in liver transplant candidates. Liver Transpl Surg 1997;3:494-500.
31. Humbert M, Labrune P, Sitbon O, Le Gall C, Callebert J, Hervé P, et al. Pulmonary arterial hypertension and type-I glycogen-storage disease: the serotonin hypothesis. Eur Respir J 2002;20:59-65.
32. Lane KB, Machado RD, Pauciulo MW, Thomson JR, Phillips JA, Loyd JE, et al. Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension. The International PPH Consortium. Nat Genet 2000;26:81-84.
33. Thomson JR, Machado RD, Pauciulo MW, Morgan NV, Humbert M, Elliott GC, et al. Sporadic primary pulmonary hypertension is associated with germline mutations of the gene encoding BMPR-II, a receptor member of the TGF-beta family. J Med Genet 2000;37: 741-745.
34. Trembath RC, Thomson JR, Machado RD, Morgan NV, Atkinson C, Winship I, et al. Clinical and molecular genetic features of pulmonary hypertension in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2001;345:325-334.